dalteparin has been researched along with lactic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Javot, L; Lecompte, T; Maincent, P; Rabiskova, M | 1 |
| Gaitani, CM; Marchetti, JM; Oliveira, FS; Oliveira, SS | 1 |
| Fu, Q; He, Z; Kou, L; Sun, J; Wang, J; Wang, Y; Wu, L; Xu, M; Zhang, P | 1 |
3 other study(ies) available for dalteparin and lactic acid
| Article | Year |
|---|---|
Encapsulation of low molecular weight heparins: influence on the anti-Xa/anti-IIa ratio.
Topics: Anticoagulants; Capsules; Deoxycholic Acid; Dimethyl Sulfoxide; Drug Compounding; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Lactic Acid; Nadroparin; Nephelometry and Turbidimetry; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymethacrylic Acids; Polymethyl Methacrylate; Prothrombin; Tinzaparin | 2009 |
Microparticles as a strategy for low-molecular-weight heparin delivery.
Topics: Anticoagulants; Capsules; Delayed-Action Preparations; Drug Compounding; Enoxaparin; Humans; Lactic Acid; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Venous Thrombosis | 2011 |
Novel nanostructured enoxaparin sodium-PLGA hybrid carriers overcome tumor multidrug resistance of doxorubicin hydrochloride.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Proliferation; Cell Survival; Doxorubicin; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endocytosis; Enoxaparin; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; MCF-7 Cells; Mice; Nanostructures; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley | 2016 |